Idera Pharmaceuticals Inc., of Cambridge, Mass., said it completed the phase I portion of the phase I/II trial testing intratumoral IMO-2125, an agonist of TLR9, in combination with Yervoy (ipilimumab, Bristol-Myers Squibb Co.) in anti-PD-1-refractory metastatic melanoma.